Recognizing our Heroes of Chemistry
Who are our heroes today? The media recognizes athletes and entertainers, as well as policemen and firefighters as heroes. At the American Chemical Society (ACS), we appreciate that chemical scientists are everyday heroes who impact our world in ways both great and small.
Since 1996, the ACS Heroes of Chemistry program has recognized chemical scientists whose work in various fields of chemistry and chemical engineering has led to the successful innovation and development of commercial products based on chemistry. The Heroes program also highlights the vital role of industrial chemical scientists and their companies in improving human welfare through successful commercial innovations and products. It presents an ideal opportunity to enhance the public image of the chemical and allied industries.
Each year, Heroes of Chemistry are nominated by their respective companies to recognize their talent, creativity, and innovation. Our previous Heroes have excelled in innovation at prominent international corporations, and have developed numerous commercial products that demonstrate strong financial performance. The commercial success of their products in the marketplace is an important criterion for this honor, because we recognize that good business results follow good science.
2015 Heroes of Chemistry
Eliquis® (apixaban), an orally bioavailable small molecule Factor Xa (FXa) inhibitor that is administered as a safe and efficacious oral anticoagulant agent during the treatment of cardiovascular disease.
POMALYST® (pomalidomide), an oral immunomodulatory agent to treat relapsed multiple myeloma cancer.
INSITE™ technology, a single-site, constrained-geometry metallocene catalysis platform that led to creation of novel polyethylene elastomers marketed under the brand names ENGAGE™, NORDEL™, and AFFINITY™.
Eastman Chemical Company
Tritan™ Copolyesters, a new family of engineering plastics that are clear, tough, stain-resistant, and free of Estrogenic Activity (EA).
Gilead Sciences, Inc.
Harvoni®, the first single-tablet regimen (STR), for the treatment of Hepatitis C virus. Harvoni® is a combination drug containing Sofosbuvir and Ledipasvir.
Xeljanz® (tofacitinib citrate), a revolutionary oral therapy for the treatment of rheumatoid arthritis. Xeljanz® is the first oral kinase inhibitor approved for a non oncology indication.